Because BCAT1's effects appear to be LSC-specific and gabapentin is commonly accessible and suitable for clinical application, it is fascinating to observe if clinical ways to utilize BCAT1 as a targeted therapy in myeloid leukemias are being developed. The gene discussed is BCAT1; the disease is myeloid leukemia.